A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther) (Panther)

A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)

The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.

Study Overview

• Status: Unknown
• Conditions: Metastatic Clear Cell Renal Cancer

Detailed Description

This is a Phase II, open label study evaluating pre-operative pazopanib treatment in previously untreated patients with metastatic clear cell renal cancer. This study follows a Simon 2 stage design

Patients will take pazopanib for 14 weeks followed by a nephrectomy. The drug will continue after nephrectomy until disease progression is documented. Patients will come off study once disease progression occurs, where they will then be followed for survival. Subsequent treatment at the discretion of the treating physician will be documented.

After surgery, all patients will be radiologically evaluated 8 weekly until progression. Standard radical nephrectomy with lymph node dissection will be performed on those patients who are deemed operable. The surgery can be laparoscopic or open. Those not deemed suitable for nephrectomy after 14 weeks of treatment will be offered a repeat biopsy.

• Study Type: Observational
• Enrollment (Anticipated): 95

Contacts and Locations

Study Locations

• United Kingdom
  • Basildon, United Kingdom
    • Basildon and Thurrock University Hospitals NHS Foundation Trust
  • Coventry, United Kingdom
    • University Hospitals Coventry & Warwickshire NHS Trust
  • Glasgow, United Kingdom
    • The Beatson West of Scotland Cancer Centre
  • London, United Kingdom
    • Barts and London Hospital NHS Trust
  • London, United Kingdom
    • Oncology & Clinical Haematology Trials Unit, Royal Free Hospital
  • London, United Kingdom
    • Oncology & Haematology Clinical Trials Unit, Guy's Hospital
  • Oxford, United Kingdom
    • Department of Oncology Oxford Cancer Centre
  • Southampton, United Kingdom
    • Southampton General Hospital
  • Southend, United Kingdom
    • Southend University Hospital Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The study population for this trial are patients with confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST). Only a component of clear cell is required.

Description

Inclusion Criteria:

• Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST v1.1). Only a component of clear cell is required.

  • No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions.

  • Adequate organ function as defined by the following criteria:

    i. Total serum bilirubin ≤1.5 x uln (patients with gilbert's disease exempt) ii. Serum transaminases (ALT) <3 x uln iii. Calculated creatinine clearance >30ml/min iv. Absolute neutrophil count (ANC) ≥1000/mm3 without growth factor support v. Platelets ≥ 75,000/mm3

  • Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
  • Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
  • ECOG performance status of 0, 1 or 2.
  • 18 years or above (no upper age limit) Male or female

Exclusion Criteria:

• Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication.

  • Previous treatment for renal cancer
  • Pregnancy or breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy.
  • Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study
  • Prolonged QT interval >480msecs or a history of prolonged QT interval >480msecs
  • Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease.
  • Bleeding diathesis
  • Current uncontrolled hypertension
  • Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical benefit of 14 weeks of pre-operative pazopanib therapy, prior to nephrectomy using RECIST 1.1 criteria	12 week CT scan will be compared to the baseline CT scan using RESIST criteria 1.1 to assess whether the patients have benefited from the upfront pazopanib treatment.	Interim analysis after 34 patients have 12 weeks of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Surgical complications (blood loss, post operative complications, hospital stay)	Following surgery information regarding the quantity of blood loss, time the surgery took, length of hospital stay and whether there were any surgical complications will be recorded.	After the first 20 patients have had a nephrectomy
Overall Survival	Overall survival will be measured from start of treatment to time of death.	After three years of study
Progression free survival	Progression free survival will be measured from start of study treatment to time of disease progression.	After all patients have progresssed
Local response of primary tumour to pazopanib		After 12 weeks of study drug

Collaborators and Investigators

• Sponsor: Queen Mary University of London

Study record dates

Study Major Dates

• Study Start: July 1, 2010
• Primary Completion (Actual): February 1, 2014
• Study Completion (Anticipated): December 1, 2014

Study Registration Dates

• First Submitted: October 4, 2011
• First Submitted That Met QC Criteria: January 13, 2012
• First Posted (Estimate): January 19, 2012

Study Record Updates

• Last Update Posted (Estimate): June 12, 2014
• Last Update Submitted That Met QC Criteria: June 11, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Keywords: Clear cell renal cancer
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Carcinoma, Renal Cell
• Other Study ID Numbers: 2009-016675-29